Publication | Closed Access

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)

OncologyAdjuvant Ado-trastuzumab EmtansineMedicineAtempt TrialClinical TrialsPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyCancer ResearchChemotherapy-related Amenorrhea